ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery - Acelyrin ( NASDAQ:SLRN )

a week ago

Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes

Ticker	Sentiment	Impact
SLRN	Somewhat Bullish	61 %